Immune-inducing strategies can increase the sensitivity of breast cancer to PD-1 blocking

In the first phase of an adaptive non-comparative Phase 2 clinical study, researchers from research institutions such as the Netherlands Cancer Institute randomly assigned 67 metastatic TNBC patients to one of the following treatment strains: (1) Navu-monoantigen, but not induced by chemotherapy or radiotherapy; (2) Navu-mono, and 2-week low-dose radiotherapy (3 x 8 Gy) induced; called radiotherapy group; (3) Navudan resistance, and received 2 weeks of low-dose cyclophosphamide induction, called cyclophosphamide group; (4) Navuda anti, and received 2 weeks low dose of cisplatin induction, called cisplatin group; (5) Navumono resistance, and received 2 weeks of low dose amycin, called amycin; all patients were subsequently used navumonoThe findings were recently published in the journal Nature Medicine, with the title "Immune induction strategies in metastatic triple negative-breast cancer to enhance the people to PD-1 blockade: the TONIC trial"images from Nature Medicine, 2019, doi:10.1038/s41591-019-0432-4.4the objective response rate (ORR; iRECIST) is 20% in this entire queueMost of the reactions were observed in the cisplatin group (ORR 23%) and amycin (ORR 35%)After amycin and cisplatin induction, the researchers detected an increase in immune-related genes in the PD-1/PD-L1 and T-cytotoxic pathwaysThis is further supported by the enrichment of upward genes associated with inflammation, JAK-STAT, and TNF-alpha signal transduction after amycin inductionthis can be seen, clinical data translation data from this clinical study suggest that short-term amycin and cisplatin therapy may induce a more favorable tumor microenvironment and increase the likelihood of responding to TNBC's response to PD-1 blockingThe data also needs to be more confirmed on TNBC and explore the possibility of induced treatment before PD-1 blocking therapy in other cancer typesreferences: Leonie Voorwerk et alImmune induction strategies in metastatic triple negative-breast cancer to enhance the people to PD-1 blockade: the TONIC trialNature Medicine, 2019, doi:10.1038/s41591-019-0432-4.